Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 2
2011 1
2012 1
2014 3
2015 2
2016 1
2017 2
2018 3
2019 6
2020 1
2021 2
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean agostino nardone (37 results)?
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Hermida-Prado F, et al. Among authors: nardone a. Cancer Res. 2023 Oct 2;83(19):3284-3304. doi: 10.1158/0008-5472.CAN-23-1711. Cancer Res. 2023. PMID: 37450351 Free PMC article.
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A, Qiu X, Spisak S, Nagy Z, Feiglin A, Feit A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, Cornwell M, Liu W, Ors A, Mohammed H, Cejas P, Brock JB, Freedman ML, Winer EP, Fu X, Schiff R, Long HW, Metzger Filho O, Jeselsohn R. Nardone A, et al. Cancer Res. 2022 Oct 17;82(20):3673-3686. doi: 10.1158/0008-5472.CAN-21-3186. Cancer Res. 2022. PMID: 35950920 Free PMC article.
Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer.
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, Zhang Q, Freelander A, Leventhal MJ, Feit A, Cohen Feit G, Feiglin A, Liu W, Hermida-Prado F, Kesten N, Ma W, De Angelis C, Morlando A, O'Donnell M, Naumenko S, Huang S, Nguyen QD, Huang Y, Malorni L, Bergholz Villafane JS, Zhao JJ, Fraenkel E, Lim E, Schiff R, Shapiro GI, Jeselsohn R. Guarducci C, et al. Among authors: nardone a. Clin Cancer Res. 2024 Feb 21. doi: 10.1158/1078-0432.CCR-23-2975. Online ahead of print. Clin Cancer Res. 2024. PMID: 38381406
The changing role of ER in endocrine resistance.
Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. Nardone A, et al. Breast. 2015 Nov;24 Suppl 2(0 2):S60-6. doi: 10.1016/j.breast.2015.07.015. Epub 2015 Aug 10. Breast. 2015. PMID: 26271713 Free PMC article. Review.
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Fu X, Pereira R, Liu CC, De Angelis C, Shea MJ, Nanda S, Qin L, Mitchell T, Cataldo ML, Veeraraghavan J, Sethunath V, Giuliano M, Gutierrez C, Győrffy B, Trivedi MV, Cohen O, Wagle N, Nardone A, Jeselsohn R, Rimawi MF, Osborne CK, Schiff R. Fu X, et al. Among authors: nardone a. Cell Rep. 2023 Aug 29;42(8):112821. doi: 10.1016/j.celrep.2023.112821. Epub 2023 Jul 18. Cell Rep. 2023. PMID: 37467106 Free article.
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.
Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Getz G, Jeselsohn R. Tsuji J, et al. Among authors: nardone a. Clin Cancer Res. 2022 Dec 1;28(23):5066-5078. doi: 10.1158/1078-0432.CCR-22-2305. Clin Cancer Res. 2022. PMID: 36215125 Free PMC article. Clinical Trial.
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I, Romagnoli D, Galardi F, De Luca F, Biagioni C, Curigliano G, Criscitiello C, Minisini AM, Moretti E, Risi E, Guarducci C, Nardone A, Biganzoli L, Benelli M, Malorni L. Migliaccio I, et al. Among authors: nardone a. JCO Precis Oncol. 2024 Feb;8:e2300285. doi: 10.1200/PO.23.00285. JCO Precis Oncol. 2024. PMID: 38427931 Clinical Trial.
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.
Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M. Jeselsohn R, et al. Among authors: nardone a. Cancer Cell. 2018 Feb 12;33(2):173-186.e5. doi: 10.1016/j.ccell.2018.01.004. Cancer Cell. 2018. PMID: 29438694 Free PMC article.
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M. Jeselsohn R, et al. Among authors: nardone a. Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4482-E4491. doi: 10.1073/pnas.1620993114. Epub 2017 May 15. Proc Natl Acad Sci U S A. 2017. PMID: 28507152 Free PMC article.
31 results